Newsbenzinga
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
· Published
Article summary
EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
An excerpt from the original article.
Comments —
Loading comments…